Therapeutic Targeting of RAS Mutant Cancers

Discover the groundbreaking insights in "Therapeutic Targeting of RAS Mutant Cancers" by Edward C. Stites, published by Cambridge University Press in 2022. This essential paperback edition spans 75 pages and delves into the complexities of the KRAS oncogene, recognized as the most prevalent single nucleotide variant oncogene in human cancer. Historically, targeting KRAS and other RAS GTPases has posed significant challenges for researchers and clinicians alike. However, this book highlights recent advancements in identifying and leveraging unique characteristics of specific oncogenic mutations. Perfect for medical professionals, researchers, and students, this text offers a comprehensive overview of the evolving landscape of cancer therapy, focusing on innovative strategies to combat RAS mutant cancers. Enhance your understanding of this critical area in oncology with Stites' expert perspectives and contribute to the ongoing dialogue in cancer treatment.